nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—LRRK2—Allograft Rejection—CXCL11—nasal cavity cancer	0.0481	0.0481	CbGpPWpGaD
Ruxolitinib—CAMK1—BDNF signaling pathway—FRS2—nasal cavity cancer	0.0359	0.0359	CbGpPWpGaD
Ruxolitinib—RET—Signaling events regulated by Ret tyrosine kinase—FRS2—nasal cavity cancer	0.0345	0.0345	CbGpPWpGaD
Ruxolitinib—JAK1—Frs2-mediated activation—FRS2—nasal cavity cancer	0.0285	0.0285	CbGpPWpGaD
Ruxolitinib—JAK1—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.0268	0.0268	CbGpPWpGaD
Ruxolitinib—TYK2—Frs2-mediated activation—FRS2—nasal cavity cancer	0.021	0.021	CbGpPWpGaD
Ruxolitinib—TYK2—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.0198	0.0198	CbGpPWpGaD
Ruxolitinib—PLK1—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.0185	0.0185	CbGpPWpGaD
Ruxolitinib—JAK1—Signalling to ERKs—FRS2—nasal cavity cancer	0.0181	0.0181	CbGpPWpGaD
Ruxolitinib—JAK1—FRS2-mediated cascade—FRS2—nasal cavity cancer	0.0181	0.0181	CbGpPWpGaD
Ruxolitinib—JAK3—SHP2 signaling—FRS2—nasal cavity cancer	0.0169	0.0169	CbGpPWpGaD
Ruxolitinib—JAK2—Frs2-mediated activation—FRS2—nasal cavity cancer	0.0159	0.0159	CbGpPWpGaD
Ruxolitinib—JAK2—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.015	0.015	CbGpPWpGaD
Ruxolitinib—JAK1—SHP2 signaling—FRS2—nasal cavity cancer	0.0145	0.0145	CbGpPWpGaD
Ruxolitinib—TYK2—FRS2-mediated cascade—FRS2—nasal cavity cancer	0.0134	0.0134	CbGpPWpGaD
Ruxolitinib—TYK2—Signalling to ERKs—FRS2—nasal cavity cancer	0.0134	0.0134	CbGpPWpGaD
Ruxolitinib—IRAK1—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.0119	0.0119	CbGpPWpGaD
Ruxolitinib—MAP3K7—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.0112	0.0112	CbGpPWpGaD
Ruxolitinib—JAK1—IRS-mediated signalling—FRS2—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Ruxolitinib—JAK1—IRS-related events—FRS2—nasal cavity cancer	0.0104	0.0104	CbGpPWpGaD
Ruxolitinib—JAK1—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.0103	0.0103	CbGpPWpGaD
Ruxolitinib—JAK2—Signalling to ERKs—FRS2—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Ruxolitinib—JAK2—FRS2-mediated cascade—FRS2—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Ruxolitinib—MAP3K2—BDNF signaling pathway—FRS2—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Ruxolitinib—JAK1—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.01	0.01	CbGpPWpGaD
Ruxolitinib—JAK1—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.01	0.01	CbGpPWpGaD
Ruxolitinib—PRKCE—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00941	0.00941	CbGpPWpGaD
Ruxolitinib—IRAK1—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.00932	0.00932	CbGpPWpGaD
Ruxolitinib—PRKCE—Downstream signal transduction—FRS2—nasal cavity cancer	0.00885	0.00885	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by FGFR—FRS2—nasal cavity cancer	0.0088	0.0088	CbGpPWpGaD
Ruxolitinib—MAP3K7—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.00878	0.00878	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00876	0.00876	CbGpPWpGaD
Ruxolitinib—PRKCE—DAP12 signaling—FRS2—nasal cavity cancer	0.00872	0.00872	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00835	0.00835	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0082	0.0082	CbGpPWpGaD
Ruxolitinib—PRKCE—DAP12 interactions—FRS2—nasal cavity cancer	0.0082	0.0082	CbGpPWpGaD
Ruxolitinib—JAK2—SHP2 signaling—FRS2—nasal cavity cancer	0.00813	0.00813	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by EGFR—FRS2—nasal cavity cancer	0.00813	0.00813	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00806	0.00806	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by PDGF—FRS2—nasal cavity cancer	0.00802	0.00802	CbGpPWpGaD
Ruxolitinib—TYK2—IRS-mediated signalling—FRS2—nasal cavity cancer	0.0079	0.0079	CbGpPWpGaD
Ruxolitinib—TYK2—IRS-related events—FRS2—nasal cavity cancer	0.00769	0.00769	CbGpPWpGaD
Ruxolitinib—TYK2—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.00762	0.00762	CbGpPWpGaD
Ruxolitinib—TYK2—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.00742	0.00742	CbGpPWpGaD
Ruxolitinib—TYK2—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.00742	0.00742	CbGpPWpGaD
Ruxolitinib—PRKCE—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00726	0.00726	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00714	0.00714	CbGpPWpGaD
Ruxolitinib—JAK1—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00683	0.00683	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00673	0.00673	CbGpPWpGaD
Ruxolitinib—JAK1—Downstream signal transduction—FRS2—nasal cavity cancer	0.00642	0.00642	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by FGFR—FRS2—nasal cavity cancer	0.00639	0.00639	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00636	0.00636	CbGpPWpGaD
Ruxolitinib—JAK1—DAP12 signaling—FRS2—nasal cavity cancer	0.00633	0.00633	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00616	0.00616	CbGpPWpGaD
Ruxolitinib—JAK2—IRS-mediated signalling—FRS2—nasal cavity cancer	0.00599	0.00599	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00595	0.00595	CbGpPWpGaD
Ruxolitinib—JAK1—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00595	0.00595	CbGpPWpGaD
Ruxolitinib—JAK1—DAP12 interactions—FRS2—nasal cavity cancer	0.00595	0.00595	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by EGFR—FRS2—nasal cavity cancer	0.0059	0.0059	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00585	0.00585	CbGpPWpGaD
Ruxolitinib—JAK2—IRS-related events—FRS2—nasal cavity cancer	0.00583	0.00583	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by PDGF—FRS2—nasal cavity cancer	0.00582	0.00582	CbGpPWpGaD
Ruxolitinib—JAK2—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.00577	0.00577	CbGpPWpGaD
Ruxolitinib—JAK2—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.00562	0.00562	CbGpPWpGaD
Ruxolitinib—JAK2—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.00562	0.00562	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by NGF—FRS2—nasal cavity cancer	0.00559	0.00559	CbGpPWpGaD
Ruxolitinib—JAK1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00527	0.00527	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00527	0.00527	CbGpPWpGaD
Ruxolitinib—TYK2—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00504	0.00504	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00496	0.00496	CbGpPWpGaD
Ruxolitinib—TYK2—Downstream signal transduction—FRS2—nasal cavity cancer	0.00474	0.00474	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by FGFR—FRS2—nasal cavity cancer	0.00472	0.00472	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00469	0.00469	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 signaling—FRS2—nasal cavity cancer	0.00467	0.00467	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00467	0.00467	CbGpPWpGaD
Ruxolitinib—MAP3K7—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00447	0.00447	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0044	0.0044	CbGpPWpGaD
Ruxolitinib—TYK2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0044	0.0044	CbGpPWpGaD
Ruxolitinib—TYK2—DAP12 interactions—FRS2—nasal cavity cancer	0.0044	0.0044	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by EGFR—FRS2—nasal cavity cancer	0.00436	0.00436	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00432	0.00432	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by PDGF—FRS2—nasal cavity cancer	0.0043	0.0043	CbGpPWpGaD
Ruxolitinib—MAP3K7—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00426	0.00426	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by NGF—FRS2—nasal cavity cancer	0.00406	0.00406	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.004	0.004	CbGpPWpGaD
Ruxolitinib—MAP3K7—B Cell Activation—FRS2—nasal cavity cancer	0.00395	0.00395	CbGpPWpGaD
Ruxolitinib—JAK2—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00393	0.00393	CbGpPWpGaD
Ruxolitinib—TYK2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00389	0.00389	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00382	0.00382	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00379	0.00379	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00376	0.00376	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00369	0.00369	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signal transduction—FRS2—nasal cavity cancer	0.00359	0.00359	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR—FRS2—nasal cavity cancer	0.00358	0.00358	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00356	0.00356	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 signaling—FRS2—nasal cavity cancer	0.00354	0.00354	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00347	0.00347	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00345	0.00345	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00333	0.00333	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 interactions—FRS2—nasal cavity cancer	0.00333	0.00333	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00333	0.00333	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—FRS2—nasal cavity cancer	0.0033	0.0033	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00327	0.00327	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—FRS2—nasal cavity cancer	0.00326	0.00326	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—FRS2—nasal cavity cancer	0.00319	0.00319	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00314	0.00314	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—FRS2—nasal cavity cancer	0.00308	0.00308	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—FRS2—nasal cavity cancer	0.00299	0.00299	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00295	0.00295	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—FRS2—nasal cavity cancer	0.00292	0.00292	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00291	0.00291	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00276	0.00276	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00271	0.00271	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—FRS2—nasal cavity cancer	0.00264	0.00264	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0025	0.0025	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00246	0.00246	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—FRS2—nasal cavity cancer	0.00231	0.00231	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—FRS2—nasal cavity cancer	0.00227	0.00227	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—FRS2—nasal cavity cancer	0.00217	0.00217	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—FRS2—nasal cavity cancer	0.00204	0.00204	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CXCL11—nasal cavity cancer	0.00204	0.00204	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—FRS2—nasal cavity cancer	0.00186	0.00186	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—FRS2—nasal cavity cancer	0.00185	0.00185	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00185	0.00185	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—FRS2—nasal cavity cancer	0.00176	0.00176	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00172	0.00172	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—FRS2—nasal cavity cancer	0.00171	0.00171	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—FRS2—nasal cavity cancer	0.0017	0.0017	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—FRS2—nasal cavity cancer	0.00166	0.00166	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—FRS2—nasal cavity cancer	0.00166	0.00166	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—FRS2—nasal cavity cancer	0.00159	0.00159	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—FRS2—nasal cavity cancer	0.00157	0.00157	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00154	0.00154	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00148	0.00148	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00145	0.00145	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0014	0.0014	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—FRS2—nasal cavity cancer	0.00135	0.00135	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—FRS2—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—FRS2—nasal cavity cancer	0.0012	0.0012	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00112	0.00112	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00109	0.00109	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL11—nasal cavity cancer	0.00106	0.00106	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—FRS2—nasal cavity cancer	0.00102	0.00102	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—FRS2—nasal cavity cancer	0.00101	0.00101	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—FRS2—nasal cavity cancer	0.000995	0.000995	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—FRS2—nasal cavity cancer	0.000965	0.000965	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—FRS2—nasal cavity cancer	0.000918	0.000918	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—FRS2—nasal cavity cancer	0.000871	0.000871	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—FRS2—nasal cavity cancer	0.000857	0.000857	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL11—nasal cavity cancer	0.000827	0.000827	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—FRS2—nasal cavity cancer	0.000754	0.000754	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—FRS2—nasal cavity cancer	0.000696	0.000696	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FRS2—nasal cavity cancer	0.000662	0.000662	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FRS2—nasal cavity cancer	0.000643	0.000643	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FRS2—nasal cavity cancer	0.000624	0.000624	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FRS2—nasal cavity cancer	0.000487	0.000487	CbGpPWpGaD
